A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients with Previously Treated, Unresectable Myxoid Liposarcoma (Alliance A091202)(CIRB)
The purpose of this study is to assess the safety and effectiveness of efatutazone in patients with myxoid liposarcoma that continues to grow despite at least one prior regimen of therapy and cannot be surgically removed. Efatutazone induces liposarcoma cell death by activating a protein called PPAR-gamma.
Patients in this study will be randomly assigned to receive efatutazone or a placebo (inactive drug). Efatutazone is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have myxoid liposarcoma that has continued to grow despite at least one prior regimen of therapy and cannot be removed surgically.
- At least 4 weeks must pass between completion of prior therapies and entry into the study.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Mark A. Dickson at 646-888-4164.